SMARCB1/INI1保留的上皮样肉瘤中SWI/SNF染色质重塑复合物的状态

免疫组化抗体神器

好评必备! 免费下载

  ——本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意,否则追究法律责任。

  SWI/SNF染色质重塑复合物是由进化保守的核心亚基组成,如SMARCB1/INI1(INI1)、SMARCA4/BRG1(BRG1)、SMARCC1/BAF155(BAF155)和SMARCC2/BAF170(BAF170),可被视为参与肿瘤抑制基因表达的表观遗传调节因子的原型。上皮样肉瘤是一种细胞分化方向尚不明确的肿瘤,几乎均有INI1的缺失。然而,一些上皮样肉瘤保留了INI1,这些肿瘤的临床病理特征尚不明确。迄今为止,还没有针对INI1保留的上皮样肉瘤中SWI/SNF染色质重塑复合物的研究。首先,对60例福尔马林固定石蜡包埋的上皮样肉瘤标本(近端型,29例;经典型,31例)进行INI1状态的免疫组织化学检测。在获得的INI1保留的上皮样肉瘤病例中分析BRG1、BAF155和BAF170蛋白的表达情况。在6例(21%;6/29)近端型和2例(6%;2/31)经典型上皮样肉瘤中观察到了INI1的存在。6例近端型INI1保留的上皮样肉瘤可用于进一步的免疫组织化学研究。其中1例近端型显示BAF170缺失,2例近端型显示BRG1缺失,同时保留其他核心亚基蛋白。1例近端型显示马赛克样的BRG1模式和BAF155的缺失。然而,在剩余2例近端型病例中,所有的核心亚单位蛋白均存在。总之,这些结果表明,SWI/SNF染色质重塑复合蛋白表达的缺失在肿瘤发生中具有重要作用。剩余2例INI1保留的上皮样肉瘤病例可能有其他异常导致的SWI/SNF染色质重塑功能障碍。
Am J Surg Pathol 2018;42:312-318
美国外科病理学杂志中文版2018年第三期摘要No.7
何鑫 翻译 张红英 审校
  The American Journal of Surgical Pathology中文版声明:
  ©2018 Wolters Kluwer Health
  The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.
  Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
 
  【本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意 ,否则追究法律责任;所有文章仅供公益交流,不代表本站立场。欢迎提供素材、资料等,投稿邮箱: tougao@91360.com,一经采纳将给予稿费】
责任编辑: 夢奕新
0 0 0

扫一扫下载91360客户端